Synthesis and preliminary evaluation of novel 11C-labeled GluN2B-selective NMDA receptor negative allosteric modulators

[1]  S. Zoghbi,et al.  Evaluation of 11C-NR2B-SMe and Its Enantiomers as PET Radioligands for Imaging the NR2B Subunit Within the NMDA Receptor Complex in Rats , 2020, The Journal of Nuclear Medicine.

[2]  Shanshan Huang,et al.  Label-Free Visualization of Early Cancer Hepatic Micrometastasis and Intraoperative Image-Guided Surgery by Photoacoustic Imaging , 2019, The Journal of Nuclear Medicine.

[3]  S. Ametamey,et al.  Structure-Affinity Relationships of 2,3,4,5-Tetrahydro-1H-3-benzazepine and 6,7,8,9-Tetrahydro-5H-benzo[7]annulen-7-amine Analogues and the Discovery of a Radiofluorinated 2,3,4,5-Tetrahydro-1H-3-benzazepine Congener for Imaging GluN2B Subunit-Containing N-Methyl-d-aspartate Receptors. , 2019, Journal of medicinal chemistry.

[4]  P. Riss,et al.  Synthesis and Characterization in Rodent Brain of the Subtype-Selective NR2B NMDA Receptor Ligand [11C]Ro04-5595 as a Potential Radiotracer for Positron Emission Tomography , 2019, ACS omega.

[5]  Liming Nie,et al.  Rapid one-step 18F-radiolabeling of biomolecules in aqueous media by organophosphine fluoride acceptors , 2019, Nature Communications.

[6]  Steven H. Liang,et al.  Chemistry for Positron Emission Tomography: Recent Advances in 11 C-, 18 F-, 13 N-, and 15 O-Labeling Reactions. , 2019, Angewandte Chemie.

[7]  Steven H. Liang,et al.  Synthesis and Preliminary Evaluations of a Triazole-Cored Antagonist as a PET Imaging Probe ([18F]N2B-0518) for GluN2B Subunit in the Brain. , 2019, ACS chemical neuroscience.

[8]  S. Ametamey,et al.  Preclinical Evaluation of Benzazepine-Based PET Radioligands (R)- and (S)-11C-Me-NB1 Reveals Distinct Enantiomeric Binding Patterns and a Tightrope Walk Between GluN2B- and σ1-Receptor–Targeted PET Imaging , 2019, The Journal of Nuclear Medicine.

[9]  N. Carruthers,et al.  1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators. , 2019, ACS medicinal chemistry letters.

[10]  T. Suhara,et al.  Synthesis and characterization of 11 C-labeled benzyl amidine derivatives as PET radioligands for GluN2B subunit of the NMDA receptors. , 2018, Journal of labelled compounds & radiopharmaceuticals.

[11]  A. Lammertsma,et al.  Evaluation of the Novel PET Tracer [11C]HACH242 for Imaging the GluN2B NMDA Receptor in Non-Human Primates , 2018, Molecular Imaging and Biology.

[12]  Steven H. Liang,et al.  Positron Emission Tomography (PET) Ligand Development for Ionotropic Glutamate Receptors: Challenges and Opportunities for Radiotracer Targeting N-Methyl-d-aspartate (NMDA), α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA), and Kainate Receptors. , 2018, Journal of medicinal chemistry.

[13]  S. Ametamey,et al.  Identification and Preclinical Evaluation of a Radiofluorinated Benzazepine Derivative for Imaging the GluN2B Subunit of the Ionotropic NMDA Receptor , 2018, The Journal of Nuclear Medicine.

[14]  S. Ametamey,et al.  Fluorinated GluN2B Receptor Antagonists with a 3‐Benzazepine Scaffold Designed for PET Studies , 2018, ChemMedChem.

[15]  Lu Wang,et al.  In Vitro and in Vivo Evaluation of 11C-Labeled Azetidinecarboxylates for Imaging Monoacylglycerol Lipase by PET Imaging Studies. , 2018, Journal of medicinal chemistry.

[16]  S. Ametamey,et al.  Evaluation of 11C-Me-NB1 as a Potential PET Radioligand for Measuring GluN2B-Containing NMDA Receptors, Drug Occupancy, and Receptor Cross Talk , 2017, The Journal of Nuclear Medicine.

[17]  Steven H. Liang,et al.  Synthesis and Preliminary Studies of a Novel Negative Allosteric Modulator, 7-((2,5-Dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-[11C]methoxyphenyl) quinoline-2-carboxamide, for Imaging of Metabotropic Glutamate Receptor 2. , 2017, ACS chemical neuroscience.

[18]  Mingjian Sun,et al.  Highly specific noninvasive photoacoustic and positron emission tomography of brain plaque with functionalized croconium dye labeled by a radiotracer , 2017, Chemical science.

[19]  D. Buhl,et al.  A Novel Binding Mode Reveals Two Distinct Classes of NMDA Receptor GluN2B-selective Antagonists , 2016, Molecular Pharmacology.

[20]  R. Mazhari,et al.  Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selective N‐methyl‐D‐aspartate receptor antagonist , 2015, Pharmacology research & perspectives.

[21]  G. Barreto,et al.  NMDARs in neurological diseases: a potential therapeutic target , 2015, The International journal of neuroscience.

[22]  Takeshi Fuchigami,et al.  Development of PET and SPECT Probes for Glutamate Receptors , 2015, TheScientificWorldJournal.

[23]  Shujia Zhu,et al.  Allosteric modulators of NMDA receptors: multiple sites and mechanisms. , 2015, Current opinion in pharmacology.

[24]  J. Mann,et al.  PET and SPECT tracers for glutamate receptors. , 2013, Drug discovery today.

[25]  Matthew T. Geballe,et al.  Mapping the Binding of GluN2B-Selective N-Methyl-d-aspartate Receptor Negative Allosteric Modulators , 2012, Molecular Pharmacology.

[26]  D. Luckenbaugh,et al.  A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder , 2012, Journal of clinical psychopharmacology.

[27]  S. Traynelis,et al.  New advances in NMDA receptor pharmacology. , 2011, Trends in pharmacological sciences.

[28]  Laetitia Mony,et al.  Molecular basis of positive allosteric modulation of GluN2B NMDA receptors by polyamines , 2011, The EMBO journal.

[29]  Hiro Furukawa,et al.  Subunit Arrangement and Phenylethanolamine Binding in GluN1/GluN2B NMDA Receptors , 2011, Nature.

[30]  R. Dingledine,et al.  Glutamate Receptor Ion Channels: Structure, Regulation, and Function , 2010, Pharmacological Reviews.

[31]  P. Conn,et al.  Metabotropic glutamate receptors: physiology, pharmacology, and disease. , 2010, Annual review of pharmacology and toxicology.

[32]  Hiro Furukawa,et al.  Structure of the zinc‐bound amino‐terminal domain of the NMDA receptor NR2B subunit , 2009, The EMBO journal.

[33]  J. Kew,et al.  Allosteric modulators of NR2B‐containing NMDA receptors: molecular mechanisms and therapeutic potential , 2009, British journal of pharmacology.

[34]  J. Willmann,et al.  Molecular imaging in drug development , 2008, Nature Reviews Drug Discovery.

[35]  Lars Farde,et al.  Using positron emission tomography to facilitate CNS drug development. , 2006, Trends in pharmacological sciences.

[36]  M. Bullock,et al.  The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. , 2005, Journal of neurotrauma.

[37]  P. Chazot.  The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies. , 2004, Current medicinal chemistry.

[38]  R. Waterhouse,et al.  Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[39]  J. Kemp,et al.  NMDA receptor pathways as drug targets , 2002, Nature Neuroscience.

[40]  P. Chazot,et al.  CP-101606 Pfizer Inc. , 2000, Current opinion in investigational drugs.

[41]  A. Wolf,et al.  Working Against Time: Rapid Radiotracer Synthesis and Imaging the Human Brain , 1997 .

[42]  J. Kemp,et al.  A novel mechanism of activity‐dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. , 1996, The Journal of physiology.

[43]  S. Nakanishi,et al.  Differential expression of five N‐methyl‐D‐aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats , 1994, The Journal of comparative neurology.

[44]  Y. Jan,et al.  Changing subunit composition of heteromeric NMDA receptors during development of rat cortex , 1994, Nature.

[45]  B. Sakmann,et al.  Developmental and regional expression in the rat brain and functional properties of four NMDA receptors , 1994, Neuron.

[46]  K. Sakimura,et al.  Developmental changes in distribution of NMDA receptor channel subunit mRNAs. , 1992, Neuroreport.